ATE304017T1 - Oxazolylpyrazol-derivate als kinase-inhibitoren - Google Patents

Oxazolylpyrazol-derivate als kinase-inhibitoren

Info

Publication number: ATE304017T1
Authority: AT; Austria
Prior art keywords: derivatives; oxazolylpyrazole; kinase inhibitors; oxazolyl; cancer
Prior art date: 2001-02-02

Application number

AT02714136T

Other languages

English (en)

Inventor

Daniela Berta

Eduard Felder

Anna Vulpetti

Marzia Villa

Original Assignee

Pharmacia Italia Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-02

Filing date

2002-01-28

Publication date

2005-09-15

2002-01-28 Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa

2005-09-15 Application granted granted Critical

2005-09-15 Publication of ATE304017T1 publication Critical patent/ATE304017T1/de

Links

KIWFWRIRMKCXFZ-UHFFFAOYSA-N 2-(1h-pyrazol-5-yl)-1,3-oxazole Chemical class C1=COC(C2=NNC=C2)=N1 KIWFWRIRMKCXFZ-UHFFFAOYSA-N 0.000 title abstract 2
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
102000001253 Protein Kinase Human genes 0.000 abstract 1
208000036142 Viral infection Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
108060006633 protein kinase Proteins 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000009385 viral infection Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Virology (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT02714136T 2001-02-02 2002-01-28 Oxazolylpyrazol-derivate als kinase-inhibitoren ATE304017T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0102687.1A GB0102687D0 (en)	2001-02-02	2001-02-02	Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
PCT/EP2002/000995 WO2002062804A1 (en)	2001-02-02	2002-01-28	Oxazolyl-pyrazole derivatives as kinase inhibitors

Publications (1)

Publication Number	Publication Date
ATE304017T1 true ATE304017T1 (de)	2005-09-15

Family

ID=9908031

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02714136T ATE304017T1 (de)	2001-02-02	2002-01-28	Oxazolylpyrazol-derivate als kinase-inhibitoren

Country Status (13)

Country	Link
US (1)	US7105535B2 (de)
EP (1)	EP1377589B1 (de)
JP (1)	JP2004520394A (de)
AT (1)	ATE304017T1 (de)
AU (1)	AU2002246076B2 (de)
CA (1)	CA2437260A1 (de)
DE (1)	DE60206028T2 (de)
DK (1)	DK1377589T3 (de)
ES (1)	ES2248532T3 (de)
GB (1)	GB0102687D0 (de)
MX (1)	MXPA03006863A (de)
NZ (1)	NZ527123A (de)
WO (1)	WO2002062804A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002333114B2 (en)	2001-11-30	2008-09-04	Qlt Inc.	Hydrazonopyrazole derivatives and their use as therapeutics
ATE374753T1 (de) *	2001-12-21	2007-10-15	Vernalis Cambridge Ltd	3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
WO2003086377A1 (en) *	2002-04-18	2003-10-23	Institute Of Medicinal Molecular Design. Inc.	Amide derivatives
US7847101B2 (en)	2002-07-24	2010-12-07	Valocor Therapeutics, Inc.	Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
EP2385041B1 (de)	2003-05-01	2013-09-18	Bristol-Myers Squibb Company	Pyrazolaminverbindungen, die als Kinasehemmer geeignet sind
US20050032869A1 (en) *	2003-07-08	2005-02-10	Pharmacia Italia S.P.A.	Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0317127D0 (en) *	2003-07-22	2003-08-27	Astex Technology Ltd	Pharmaceutical compounds
CA2532965C (en)	2003-07-22	2013-05-14	Astex Therapeutics Limited	3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
DE10344223A1 (de) *	2003-09-24	2005-04-21	Merck Patent Gmbh	1,3-Benzoxazolylderivate als Kinase-Inhibitoren
EP1694686A1 (de)	2003-12-19	2006-08-30	Takeda San Diego, Inc.	Kinaseinhibitoren
GB0402518D0 (en) *	2004-02-05	2004-03-10	Astrazeneca Ab	Therapeutic agents
US8354427B2 (en) *	2004-06-24	2013-01-15	Vertex Pharmaceutical Incorporated	Modulators of ATP-binding cassette transporters
LT2502911T (lt) *	2004-06-24	2017-09-11	Vertex Pharmaceuticals Incorporated	Atp surišančios kasetės transporterių moduliatoriai
US7253167B2 (en)	2004-06-30	2007-08-07	Bristol-Myers Squibb Company	Tricyclic-heteroaryl compounds useful as kinase inhibitors
JP2008505167A (ja) *	2004-07-05	2008-02-21	アステックス、セラピューティックス、リミテッド	医薬組成物
WO2006023931A2 (en)	2004-08-18	2006-03-02	Takeda San Diego, Inc.	Kinase inhibitors
EP1812439B2 (de)	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinaseinhibitoren
CN101146532B (zh) *	2005-01-21	2012-05-09	阿斯泰克斯治疗有限公司	药物化合物
RU2425677C2 (ru) *	2005-01-21	2011-08-10	Астекс Терапьютикс Лимитед	Соединения, предназначенные для использования в фармацевтике
GB0501475D0 (en) *	2005-01-22	2005-03-02	Astex Technology Ltd	Pharmaceutical compounds
US8404718B2 (en)	2005-01-21	2013-03-26	Astex Therapeutics Limited	Combinations of pyrazole kinase inhibitors
AR054425A1 (es) *	2005-01-21	2007-06-27	Astex Therapeutics Ltd	Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US20060252807A1 (en) *	2005-04-22	2006-11-09	Kalypsys, Inc.	Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
JPWO2007010731A1 (ja) *	2005-07-15	2009-01-29	Jsr株式会社	含窒素芳香族化合物およびその製造方法、重合体およびプロトン伝導膜
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
EP1945632B1 (de)	2005-11-08	2013-09-18	Vertex Pharmaceuticals Incorporated	Heterozyklische modulatoren von atp-bindenden kassettentransportern
EA200870117A1 (ru) *	2005-12-23	2008-12-30	Смитклайн Бичам Корпорейшн	Азаиндоловые ингибиторы аурора-киназ
CA2634113A1 (en) *	2005-12-24	2007-07-05	Vertex Pharmaceuticals Incorporated	Quinolin- 4 - one derivatives as modulators of abc transporters
WO2007079139A2 (en)	2005-12-28	2007-07-12	Vertex Pharmaceuticals, Inc.	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US7671221B2 (en) *	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
AU2006336504C9 (en) *	2005-12-28	2015-05-14	Vertex Pharmaceuticals Incorporated	1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
US7504513B2 (en)	2006-02-27	2009-03-17	Hoffman-La Roche Inc.	Thiazolyl-benzimidazoles
AU2007275301A1 (en) *	2006-07-20	2008-01-24	Amgen Inc.	Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
SG158147A1 (en)	2006-10-09	2010-01-29	Takeda Pharmaceutical	Kinase inhibitors
US8969386B2 (en)	2007-05-09	2015-03-03	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
EP2225235B1 (de) *	2007-10-29	2017-09-06	Merck Sharp & Dohme Corp.	Thiazolcarbonsäureamidderivate und deren verwendung zur behandlung von krebs
EP2639224B1 (de)	2007-12-07	2016-08-24	Vertex Pharmaceuticals Incorporated	Verfahren zur Herstellung von Cycloalkylcarboxamidopyridinbenzoesäuren
SI2225230T1 (sl)	2007-12-07	2017-03-31	Vertex Pharmaceuticals Incorporated	Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
NZ720282A (en)	2008-02-28	2017-12-22	Vertex Pharma	Heteroaryl derivatives as cftr modulators
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
WO2010121675A2 (en)	2008-12-18	2010-10-28	F. Hoffmann-La Roche Ag	Thiazolyl-benzimidazoles
SI2408750T1 (sl)	2009-03-20	2015-11-30	Vertex Pharmaceuticals Incorporated	Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
WO2011048018A1 (en) *	2009-10-19	2011-04-28	Boehringer Ingelheim International Gmbh	Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use
CN104958294A (zh) *	2010-01-27	2015-10-07	内尔维安诺医学科学有限公司	作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物
EP2554163A4 (de) *	2010-03-26	2013-07-17	Univ Hokkaido Nat Univ Corp	Therapeutischer wirkstoff für neurodegenerative erkrankungen
HRP20211752T1 (hr)	2010-04-07	2022-02-18	Vertex Pharmaceuticals Incorporated	Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
US8802700B2 (en)	2010-12-10	2014-08-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
WO2013112804A1 (en)	2012-01-25	2013-08-01	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2819670A1 (de)	2012-02-27	2015-01-07	Vertex Pharmaceuticals Incorporated	Pharmazeutische zusammensetzung und verabreichung davon
JP6963896B2 (ja)	2013-11-12	2021-11-10	バーテックスファーマシューティカルズインコーポレイテッドVertex Pharmaceuticals Incorporated	Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
KR20170063954A (ko)	2014-10-07	2017-06-08	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
PT3221692T (pt)	2014-11-18	2021-09-10	Vertex Pharma	Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
CA2976973A1 (en) *	2015-02-20	2016-08-25	Bayer Pharma Aktiengesellschaft	N-phenyl-(morpholin-4-yl or piperazinyl)acetamide derivatives and their use as inhibitors of the wnt signalling pathways
JOP20190156B1 (ar) *	2016-12-23	2023-09-17	Bayer Pharma AG	أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1
CN112457308B (zh) *	2019-09-09	2024-01-02	上海长森药业有限公司	新型三环芳香杂环化合物，及其制备方法、药物组合物和应用
TW202136238A (zh) *	2020-01-06	2021-10-01	大陸商廣東東陽光藥業有限公司	RORγt抑制劑及其製備方法和用途
TWI750905B (zh) *	2020-11-19	2021-12-21	財團法人國家衛生研究院	噻唑化合物作為蛋白質激酶抑制劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3722992A1 (de)	1987-07-11	1989-01-19	Thomae Gmbh Dr K	Neue imidazo-pyridine und purine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU754830C (en)	1997-05-22	2004-02-12	G.D. Searle Llc	Substituted pyrazoles as p38 kinase inhibitors
EP1077971A1 (de) *	1998-05-14	2001-02-28	G.D. SEARLE & CO.	Substituierte 1,5-diarylpyrazole als p38 kinase inhibitoren

2001
- 2001-02-02 GB GBGB0102687.1A patent/GB0102687D0/en not_active Ceased
2002
- 2002-01-28 AU AU2002246076A patent/AU2002246076B2/en not_active Expired - Fee Related
- 2002-01-28 US US10/470,859 patent/US7105535B2/en not_active Expired - Fee Related
- 2002-01-28 DK DK02714136T patent/DK1377589T3/da active
- 2002-01-28 JP JP2002563156A patent/JP2004520394A/ja active Pending
- 2002-01-28 MX MXPA03006863A patent/MXPA03006863A/es active IP Right Grant
- 2002-01-28 AT AT02714136T patent/ATE304017T1/de not_active IP Right Cessation
- 2002-01-28 ES ES02714136T patent/ES2248532T3/es not_active Expired - Lifetime
- 2002-01-28 DE DE60206028T patent/DE60206028T2/de not_active Expired - Fee Related
- 2002-01-28 WO PCT/EP2002/000995 patent/WO2002062804A1/en not_active Ceased
- 2002-01-28 CA CA002437260A patent/CA2437260A1/en not_active Abandoned
- 2002-01-28 EP EP02714136A patent/EP1377589B1/de not_active Expired - Lifetime
- 2002-01-28 NZ NZ527123A patent/NZ527123A/xx unknown

Also Published As

Publication number	Publication date
DE60206028T2 (de)	2006-06-29
US7105535B2 (en)	2006-09-12
WO2002062804A1 (en)	2002-08-15
GB0102687D0 (en)	2001-03-21
DK1377589T3 (da)	2006-01-09
AU2002246076B2 (en)	2007-06-14
JP2004520394A (ja)	2004-07-08
CA2437260A1 (en)	2002-08-15
EP1377589A1 (de)	2004-01-07
EP1377589B1 (de)	2005-09-07
US20040180881A1 (en)	2004-09-16
MXPA03006863A (es)	2003-11-13
DE60206028D1 (de)	2005-10-13
ES2248532T3 (es)	2006-03-16
NZ527123A (en)	2005-04-29

Legal Events

Date

Code

Title

Description

2006-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1377589

Country of ref document: EP

2008-10-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE60206028D1 (de)	2005-10-13	Oxazolylpyrazol-derivate als kinase-inhibitoren
MXPA04000920A (es)	2004-04-02	Derivados de aminoisoxazol activos como inhibidores de la cinasa.
EA200400283A1 (ru)	2004-08-26	Производные аминофталазинона, активные как ингибиторы киназ, способ их получения и содержащие их фармацевтические композиции
MXPA02012164A (es)	2003-04-25	Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden.
ATE411022T1 (de)	2008-10-15	Pyridylpyrrol-derivate als wirksame kinase-hemmer
MXPA04001114A (es)	2004-05-20	Derivados de aminoindazol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
DE60319158D1 (de)	2008-03-27	Pyrazoloisoquinolinenderivaten als kinase inhibitoren
MXPA05009719A (es)	2005-10-18	Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
ATE353013T1 (de)	2007-02-15	Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
NO20070514L (no)	2007-03-12	Pyrrolotriazin kinase inhibitorer
DE60314603D1 (de)	2007-08-09	Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE466580T1 (de)	2010-05-15	Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de)	2010-06-15	Azolylaminoazine als proteinkinasehemmer
ATE396986T1 (de)	2008-06-15	Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
ATE432281T1 (de)	2009-06-15	Pyrrolotriazin-kinasehemmer
NO20073113L (no)	2007-07-16	Indenylderivater og anvendelse derav for behandling av neurologiske lidelser
ATE546452T1 (de)	2012-03-15	Pyrazolopyrrolderivate als proteinkinaseinhibitoren
DE60106409D1 (de)	2004-11-18	3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
ATE287886T1 (de)	2005-02-15	Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer